BSE filing, NSE: VISTAPH. Summary written from the filing by ALFA Finder's alert engine.
Vista Pharmaceuticals Ltd: key numbers
- Share price
- ₹6.14
- Market cap
- ₹37.79 Cr
- Revenue (annual)
- ₹5.40 Cr
- Net profit (annual)
- ₹-12.06 Cr
- P/E (TTM)
- -3.2×Sector 46.1×
- Promoter holding
- 21.19%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vista Pharmaceuticals Ltd
All →Vista Pharmaceuticals Management Change
Vista Pharmaceuticals Ltd announced the resignation of Mrs. Barkha Jain as Company Secretary and Compliance Officer, effective September 4, 2026.
Vista Pharmaceuticals Q1 FY27 Results: Net Loss of ₹1 Cr, Loss Narrows
Vista Pharmaceuticals Ltd reported a net loss of ₹1 Cr for Q1 FY27.
- Key figure
- Net loss ₹1 Cr
Vista Pharmaceuticals Board Meeting Date
Vista Pharmaceuticals has scheduled a board meeting for August 14, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.
Vista Pharmaceuticals Other Announcement
Vista Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Vista Pharmaceuticals Q4 FY26 Results: Net Loss of ₹5.9 Cr, Loss Widens
Vista Pharmaceuticals Ltd reported a net loss of ₹5.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹5.9 Cr
Vista Pharmaceuticals Financial Results
Vista Pharmaceuticals reported audited financial results for the year ended March 31, 2026. The company also appointed M/s. LMN & Co. as internal auditors.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.